Scienture Holdings, Inc. (SCNX)
SCNXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.04
-0.0600 (-1.94%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $4.99m
- P/E
- –
- EPS, last 4 quarters
- $-52.50
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.64 to $19.47
- Average volume
- 188.9k
- Previous close
- $3.10
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +97.4% from here
Earnings
next estimate $-1.57Next report
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | $590.0k | $56.0k | $344.0k |
| Gross profit | – | $575.0k | $54.0k | $336.0k |
| Operating income | -$5.16m | -$4.36m | -$3.51m | -$2.70m |
| Net income | -$6.72m | -$3.61m | -$3.40m | -$2.82m |
News
8 latest- Scienture Holdings Consensus Price Target Increased by 2,400% to $38.25Fintel · Oct 23, 2026
- Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal RTTNews · Sep 22, 2026
- Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up RTTNews · Jul 10, 2026
- Scienture Granted Third USPTO Patent For Arbli Oral Solution In Treating Hypertension RTTNews · May 6, 2026
- Scienture Holdings Posts Strong Revenue Growth For 2025; Stock Down RTTNews · Mar 30, 2026
- Scienture Holdings Stock Climbs 31% After GPO Agreements For REZENOPY Naloxone Spray RTTNews · Mar 11, 2026
- Maxim Group Initiates Coverage of Scienture Holdings (SCNX) with Buy RecommendationFintel · Feb 24, 2026
- Scienture And Summit's REZENOPY Awarded Orange Book-Listable Patent, Valid Till 2041 RTTNews · Jan 14, 2026
The company
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- scienture.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.